BUFFALO, N.Y., April 19, 2011 /PRNewswire/ -- Today, H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, provided a company overview to venture capital, pharmaceutical and biotechnology industry leaders at the Celebration of Innovation Showcase 2011 hosted by the University of Florida Office of Technology Licensing at the Hilton University of Florida Conference Center Gainesville.
The University of Florida Celebration of Innovation lets select start-up companies in life sciences, medical sciences and information technology present licensing, commercialization and investment opportunities generated as a result of the $678 million in research conducted at UF.
CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumors in that its unique mechanism of action disrupts the signaling of FAK in tumors by targeting specific protein to protein bindings. CureFAKtor scientists first discovered FAK in human tumors approximately 20 years ago. FAK is much like a force field that cocoons cancer cells and allows them to survive the effects of chemotherapy, radiation and other natural processes designed to execute aberrant cancer cells. Since FAK is over-expressed in virtually all solid tumors, the technology has broad applicability in oncology.
More than 40 compounds have been identified that target FAK signaling sites. In pre-clinical studies, lead compound CFAK-C4 demonstrated efficacy in a number of cancers including pancreatic, breast, advanced melanoma and neuroblastoma. The Company's second product candidate, CFAK-Y15 is being investigated for the treatment of lung, breast, pancreatic, neuroblastoma and colon cancer. The Company has promising results with CFAK-Y15 in vitro in lung canc
|SOURCE CureFAKtor Pharmaceuticals, LLC|
Copyright©2010 PR Newswire.
All rights reserved